Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Are purely cosmetic procedures appropriate for the management of pectus excavatum? A qualitative study of pediatric surgeons.

Journal of pediatric surgery·2026

Same author

Principles of sustainable surgical and anesthetic practice.

Journal of pediatric surgery·2026

Same author

Environmental and human health impact of contact precaution use for methicillin-resistant <i>Staphylococcus aureus</i> and vancomycin-resistant <i>Enterococcus</i> in Los Angeles County.

Infection control and hospital epidemiology·2025

Same author

Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials: An Initiative From the Heart Failure Collaboratory.

JACC. Heart failure·2025

Same author

Impact of Mild and Moderate Aortic Stenosis in Acute Heart Failure: Insights From RELAX-AHF-2.

Journal of cardiac failure·2025

Same author

Sustainable surgery: Merging health care and environmental impact.

Surgery·2025

Search research articles

Related Experiment Video

Updated: May 18, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Anticoagulation in heart failure: current status and future direction.

Mihai Gheorghiade¹, Muthiah Vaduganathan, Gregg C Fonarow

¹Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 1006, Chicago, IL, 60611, USA, m-gheorghiade@northwestern.edu.

Heart Failure Reviews

|September 19, 2012

Summary

This summary is machine-generated.

Patients with heart failure (HF) face high post-discharge risks. Anticoagulation may reduce stroke risk in HF patients, but newer agents require further study for managing these high-risk individuals.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: May 18, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Cardiology
Thrombosis Research

Background:

Heart failure (HF) patients hospitalized face high mortality and readmission rates post-discharge.
A hypercoagulable state in HF contributes to morbidity and mortality, often alongside conditions like atrial fibrillation (AF) and coronary artery disease (CAD).
Acute coronary syndrome (ACS), a result of coronary thrombosis, frequently precipitates worsening HF and can cause sudden death in patients with HF and CAD.

Purpose of the Study:

To review current evidence on anticoagulation in heart failure (HF) management.
To assess the potential role of newer oral anticoagulants in reducing post-discharge events for hospitalized HF patients.

Main Methods:

Review of existing clinical trial data and observational studies on anticoagulation in HF.
Analysis of recent trial results, including the WARCEF trial and studies on newer oral anticoagulants in AF and ACS populations.

Main Results:

Anticoagulation with warfarin showed a potential reduction in stroke risk in HF patients, though primary endpoints were similar to aspirin.
Newer oral anticoagulants (dabigatran, apixaban, rivaroxaban) demonstrated benefits in AF patients with concomitant HF and in ACS patients.

Conclusions:

Current guideline recommendations for anticoagulation in HF vary due to limited data.
Further investigation into newer oral anticoagulants is warranted to improve outcomes for hospitalized HF patients with high post-discharge event rates.